Abstract
Manning et al. (Dec. 20 issue)1 elegantly demonstrated that pretreatment with MK-571, a selective leukotriene D4—receptor antagonist, markedly attenuated exercise-induced bronchoconstriction in patients with asthma. However, we have some reservations about their methods.